2018 Outstanding Investigator Award (R35)


The NCI Outstanding Investigator Award (OIA) supports investigators with outstanding records of productivity in cancer research by providing extended funding stability and encouraging investigators to continue or embark on projects of unusual potential in cancer research. The research funded will focus on exploiting novel protein kinases that regulate MYC protein stability to cause MYC loss, determining key ERK substrates that are critical for ERK-dependent KRAS-mutant PDAC growth, applying experimental approaches to define YAP1–independent mechanisms, and pursuing outlier mutations in PDAC to identify mutation-specific vulnerabilities as the basis for the development of mutation-selective therapies. These findings will help develop anti-KRAS therapies and achieve breakthroughs needed for development of anti-RAS oncogene therapies that can impair growth of PDAC.

NCI Outstanding Investigator Award Recipients was originally published by the National Cancer Institute.

The Lineberger Website Article

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s